Leadership Team
Martin Rogers
Chief Executive Officer
Mr Rogers is the Managing Director and Chief Executive Officer of Prima BioMed. He has a strong science background, which includes degrees in science and chemical engineering and is currently a member of the management committee of the National Breast Cancer Foundation. Mr Rogers also has strong expertise in the corporate sector, with a focus on the incubation and development of new business ideas. He has previously been involved in the origination of a number of new business concepts and the establishment of internal ventures and external partnerships, including finance concept origination in the corporate banking sector for institutions such as Macquarie Bank.
Matthew Lehman
Chief Operating Officer
Mr Lehman has served as our Chief Operating Officer since February 2010. Mr Lehman has experience in clinical research, development programs and obtaining drug approval. He has specific expertise in clinical development strategies, operations and in-outsourcing. From 2000 until 2010, Mr Lehman was Chief Operating Officer for SPRI Clinical Trials in the US and Europe where he managed teams in all areas of clinical operations. Mr Lehman is based in Berlin and plays a key role in leading our research and development plans, and clinical trials for its Cvac ovarian cancer therapy vaccine. Mr Lehman has a Master of Science from Columbia University in New York, and a Bachelor of Arts from the University of Louisville, Kentucky. He is also a member of the European Business Association and Association for Clinical Research Professionals.
Ian Bangs
Chief Financial Officer
Ian Bangs has over 25 years experience working in senior finance positions with companies involved in a range of diversified industries. Mr Bangs has worked as Chief Financial Officer and Company Secretary for a number of public companies listed on the ASX including LandMark White Limited, IFC Capital Limited and 10 years as the CFO of the Regent Hotel in Sydney. He has been responsible for the day to day financial and administrative operations together with the statutory reporting and compliance obligations of these organisations. He has a Bachelor of Commerce degree and is a Fellow CPA.
Dr Neil Frazer
Chief Medical Officer
Dr Frazer has more than 23 years of drug development experience in multiple therapeutic areas, including more than six years of oncology drug development experience. Dr Frazer commenced his medical career as a UK-based anesthetist working in the UK National Health Service and has worked in Europe and in the US conducting Phase I-IV studies, which have led to product registrations in Europe and the US. Prior to joining Prima BioMed, Dr Frazer held senior management roles with Glaxo and Glaxo-Wellcome and Clintrials Research, and had also held executive medical roles with PharmaLinkFHI (eCRO), Shire Pharmaceuticals, Erimos Pharmaceuticals and Chimerix, Inc.
Dr Sharron Gargosky
Senior Vice President, Cvac
Senior Vice President, Cvac Program
Dr Gargosky has 17 years experience in the biotechnology and pharmaceutical industries, and has worked in senior positions responsible for successful FDA approval for orphan drugs. She is responsible for managing the clinical team working on the Cvac immunotherapy cancer vaccine.
Prior to joining Prima, Dr Gargosky was a member of ILMU consulting LLC, where she provided project management and operational expertise on pharmaceutical drug and biologic development – from early research to Phase IV Trials and the FDA approval process. Dr Gargosky has also previously held the positions of Chief Scientific Officer at Pulse Health LLC in Portland in the USA and Chief Scientific Officer and Senior Vice President of Corporate Development at Hyperion Therapeutics Inc. in San Francisco. At Ucyclyd Pharma she managed the approval of orphan drug products (Ammonul) and the development of the NCE, and within Medics Pharmaceuticals, the successful BLA submission and approval for Reloxin. As Vice President of Business Development for Diagnostic System Laboratories she was responsible for business expansion through evaluation and implementation of new growth opportunities and patent portfolio management. Dr Gargosky has a Postdoctoral Fellowship in Pediatric Endocrinology from Stanford University in California, a PhD in biochemistry from University of Adelaide in Australia (in collaboration with CSIRO Divisions of Human Nutrition, South Australia), First Class Honors in Biochemistry from University of Adelaide, and a Bachelor of Science, Biochemistry (Distinction), Microbiology, Immunology & Virology (Distinction) from University of Adelaide.
Marc Voigt
General Manager, European Operations
Mr Voigt has extensive experience in the corporate and biotechnology sectors. He joined Prima BioMed’s management team in 2011 as the General Manager of the company’s European operations at Prima BioMed GmbH. He previously worked as an investment manager for Allianz Insurance biotech venture fund, and as a personal assistant to a member of the Executive Board of Allianz Insurance.
Mr Voigt has also worked for German investment bank, net.IPO.AG in business development and German securities offerings. In the biotech sector he held the positions of CFO/CBO at Revotar Biopharmaceuticals AG and Medical Enzymes AG. He has a Masters Degree in Business Administration from the Freie University of Berlin, and is a member of the pharma licencing club Germany and a member of the judging panel of Germany’s largest business plan competition.
Dr Hind Al Saadi
General Manager Prima BioMed Middle East
Dr Hind Al Saadi has been appointed General Manager of Prima BioMed Middle East operations and will lead the commercialisation effort for Cvac in the region. Dr Al Saadi, a pharmacist by training, has nearly 20 years of international industry experience in marketing, sales, distribution and regulatory affairs. She previously worked for Baxter Healthcare in New Zealand, as well as Globalpharma and The Center for Healthcare Planning and Quality in Dubai.
Vanessa Waddell
Business Development and Intellectual Property Manager
Ms Waddell is the Business Development Manager and Intellectual Property Manager of Prima BioMed. Previous industry experience includes technical specialist and product development roles with AMRAD Biotech. Prior to joining Prima BioMed, Ms Waddell was employed in the commercialisation company of the Austin Research Institute. Since joining Prima BioMed, Ms Waddell has overseen project management of the company's first two investments, Cancer Vac Ltd and Arthron Ltd. In addition she has assisted in the identification, evaluation and structuring of two further investments made by the company. Ms Waddell has a BSc (Hons) degree in Science from the University of Sydney and a Masters of Business Administration from Deakin University.
Larisa Chisholm
Intellectual Property Manager
Ms Chisholm has an Honours degree at LaTrobe University (1992, studying the role of Natural Killer Cells in immune surveillance of cancer). From 1993 - 1996 she worked in the same laboratory and then joined the Immunogenetics and Xenotransplantation Laboratory at the then Austin Research Institute (Burnet). In 2001 she left to complete a Masters of Business Administration at La Trobe University. Ms Chisholm joined Prima BioMed in 2003 and her understanding of the Austin Research Centre and its people has proven invaluable. She has since worked in a variety of roles including market research, Grants Coordinator. Her current role is Intellectual Property Manager and she also assists with various business development activities.
|